309 related articles for article (PubMed ID: 22261932)
1. Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells.
Kajitani K; Tanaka Y; Arihiro K; Kataoka T; Ohdan H
Breast Cancer Res Treat; 2012 Jul; 134(1):139-55. PubMed ID: 22261932
[TBL] [Abstract][Full Text] [Related]
2. Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma.
Ohira M; Nishida S; Tryphonopoulos P; Tekin A; Selvaggi G; Moon J; Levi D; Ricordi C; Ishiyama K; Tanaka Y; Ohdan H; Tzakis AG
Cell Transplant; 2012; 21(7):1397-406. PubMed ID: 22469170
[TBL] [Abstract][Full Text] [Related]
3. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans.
Ishiyama K; Ohdan H; Ohira M; Mitsuta H; Arihiro K; Asahara T
Hepatology; 2006 Feb; 43(2):362-72. PubMed ID: 16440347
[TBL] [Abstract][Full Text] [Related]
4. Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice.
Ochi M; Ohdan H; Mitsuta H; Onoe T; Tokita D; Hara H; Ishiyama K; Zhou W; Tanaka Y; Asahara T
Hepatology; 2004 May; 39(5):1321-31. PubMed ID: 15122761
[TBL] [Abstract][Full Text] [Related]
5. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells.
Kayagaki N; Yamaguchi N; Nakayama M; Takeda K; Akiba H; Tsutsui H; Okamura H; Nakanishi K; Okumura K; Yagita H
J Immunol; 1999 Aug; 163(4):1906-13. PubMed ID: 10438925
[TBL] [Abstract][Full Text] [Related]
6. Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN-γ.
Sarhan D; D'Arcy P; Wennerberg E; Lidén M; Hu J; Winqvist O; Rolny C; Lundqvist A
Eur J Immunol; 2013 Jan; 43(1):249-57. PubMed ID: 22996291
[TBL] [Abstract][Full Text] [Related]
7. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells.
Roda JM; Parihar R; Magro C; Nuovo GJ; Tridandapani S; Carson WE
Cancer Res; 2006 Jan; 66(1):517-26. PubMed ID: 16397268
[TBL] [Abstract][Full Text] [Related]
9. IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.
Roberti MP; Rocca YS; Amat M; Pampena MB; Loza J; Coló F; Fabiano V; Loza CM; Arriaga JM; Bianchini M; Barrio MM; Bravo AI; Domenichini E; Chacón R; Mordoh J; Levy EM
Breast Cancer Res Treat; 2012 Dec; 136(3):659-71. PubMed ID: 23065032
[TBL] [Abstract][Full Text] [Related]
10. Hepatectomy leads to loss of TRAIL-expressing liver NK cells via downregulation of the CXCL9-CXCR3 axis in mice.
Yano T; Ohira M; Nakano R; Tanaka Y; Ohdan H
PLoS One; 2017; 12(10):e0186997. PubMed ID: 29088306
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.
Zhang C; Zhang J; Niu J; Zhou Z; Zhang J; Tian Z
Hum Immunol; 2008 Aug; 69(8):490-500. PubMed ID: 18619507
[TBL] [Abstract][Full Text] [Related]
12. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.
Ohira M; Ohdan H; Mitsuta H; Ishiyama K; Tanaka Y; Igarashi Y; Asahara T
Transplantation; 2006 Dec; 82(12):1712-9. PubMed ID: 17198265
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-21 increases direct cytotoxicity and IFN-γ production of ex vivo expanded NK cells towards breast cancer cells.
Park YK; Shin DJ; Cho D; Kim SK; Lee JJ; Shin MG; Ryang DW; Lee JS; Park MH; Yoon JH; Jegal YJ
Anticancer Res; 2012 Mar; 32(3):839-46. PubMed ID: 22399602
[TBL] [Abstract][Full Text] [Related]
14. Irradiation of breast cancer cells enhances CXCL16 ligand expression and induces the migration of natural killer cells expressing the CXCR6 receptor.
Yoon MS; Pham CT; Phan MT; Shin DJ; Jang YY; Park MH; Kim SK; Kim S; Cho D
Cytotherapy; 2016 Dec; 18(12):1532-1542. PubMed ID: 27720639
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands.
Wendel M; Galani IE; Suri-Payer E; Cerwenka A
Cancer Res; 2008 Oct; 68(20):8437-45. PubMed ID: 18922917
[TBL] [Abstract][Full Text] [Related]
16. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.
Pahl JH; Ruslan SE; Buddingh EP; Santos SJ; Szuhai K; Serra M; Gelderblom H; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
Clin Cancer Res; 2012 Jan; 18(2):432-41. PubMed ID: 22090361
[TBL] [Abstract][Full Text] [Related]
17. Recruitment of natural killer cells in advanced stages of endogenously arising B-cell lymphoma: implications for therapeutic cell transfer.
Przewoznik M; Hömberg N; Naujoks M; Pötzl J; Münchmeier N; Brenner CD; Anz D; Bourquin C; Nelson PJ; Röcken M; Mocikat R
J Immunother; 2012 Apr; 35(3):217-22. PubMed ID: 22421939
[TBL] [Abstract][Full Text] [Related]
18. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
19. [Current advances and expectations in tumor immunology].
Takeda K; Okumura K
Hum Cell; 2001 Sep; 14(3):159-63. PubMed ID: 11774735
[TBL] [Abstract][Full Text] [Related]
20. HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab.
Yamaguchi Y; Hironaka K; Okawaki M; Okita R; Matsuura K; Ohshita A; Toge T
Anticancer Res; 2005; 25(2A):827-32. PubMed ID: 15868915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
